Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
bevacizumab (avastin) (1 trial)
capecitabine (xeloda) (3 trials)
cetuximab (erbitux) (1 trial)
cisplatin (platinol) (1 trial)
dasatinib (sprycel) (1 trial)
docetaxel (taxotere) (1 trial)
doxorubicin (Doxil) (1 trial)
erlotinib (tarceva) (2 trials)
etoposide (vepesid) (1 trial)
fluorouracil (efudex) (2 trials)
gemcitabine (gemzar) (3 trials)
irinotecan (Camptosar) (4 trials)
mitomycin (mutamycin) (1 trial)
oxaliplatin (eloxatin) (3 trials)
paclitaxel (taxol) (2 trials)
pemetrexed (alimta) (1 trial)
Raltitrexed (Tomudex) (1 trial)
sorafenib (nexavar) (1 trial)
topotecan (hycamtin) (1 trial)
vinorelbine (navelbine) (1 trial)
buparlisib (1 trial)
Adenocarcinoma (Phase 2)
Breast Neoplasms (Phase 1)
Carcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Neoplasm Metastasis (Phase 2)
Pancreatic Neoplasms (Phase 2)
Trials (6 total)
Trial APIs (21 total)